23 Apr 2018 10:09
23 April 2018
Fusion Antibodies plc
("Fusion" or the "Company")
Investor presentation
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces that it will hold a presentation for investors on Wednesday, 2 May 2018.
The briefing by Paul Kerr, CEO of Fusion will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email fusion@walbrookpr.com.
Enquiries:
Fusion Antibodies plc | www.fusionantibodies.com | |
Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR | |
James Fair, Chief Financial Officer | ||
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
Anna Dunphy | Mob: +44 (0)7876 741 001 | |
Fusion Antibody (FAB)